Inside the Clinic: Myelofibrosis

Experts from the John Theurer Cancer Center reflect on the real-world management of patients with myelofibrosis at their institution.

EP. 1: Patient Scenario 1: Diagnosis and Risk Stratification of MF

June 30th 2023

After reviewing the first patient scenario of myelofibrosis, experts from the John Theurer Cancer Center reflect on best practices in diagnosing and risk stratifying patients.

EP. 2: Molecular Markers and Subsets of Myelofibrosis

July 25th 2023

Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.

EP. 3: Optimizing MF Management With Multidisciplinary Care

July 25th 2023

A comprehensive discussion on the members of a healthcare team who might help to diagnose and manage a patient with myelofibrosis.

EP. 4: Evolving Treatment Armamentarium for Myelofibrosis

August 1st 2023

Key opinion leaders provide a broad perspective on the current treatment armamentarium available to patients diagnosed with myelofibrosis.

EP. 5: Clinical Data With Pacritinib in Patients With Myelofibrosis

August 1st 2023

Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.

EP. 6: Myelofibrosis: Potential Impact of Pacritinib on Anemia

August 8th 2023

Experts continue their conversation on pacritinib in myelofibrosis by reviewing its potential impact on anemia and ACVR1.

EP. 7: Pacritinib in Myelofibrosis: Adverse Event Management and Dosing

August 8th 2023

Shared insight on the safety profile of pacritinib and how best to mitigate or manage adverse events when they occur in patients with myelofibrosis.

EP. 8: Momelotinib’s Role in the Myelofibrosis Treatment Paradigm

August 15th 2023

Key opinion leaders on myelofibrosis management consider the potential role of momelotinib within the current treatment paradigm.

EP. 9: Patient Scenario 2: JAK2 Inhibitors in Myelofibrosis

August 15th 2023

After reviewing the second patient scenario of myelofibrosis, experts from the John Theurer Cancer Center discuss the use of JAK inhibitors, specifically ruxolitinib, to manage patients in the frontline setting.

EP. 10: Optimal Selection and Sequencing of Therapy in Patients With Myelofibrosis

August 22nd 2023

Broader perspectives on the optimal selection and sequencing of systemic therapy in patients diagnosed with myelofibrosis.